Travaux scientifiques

Prof. Dr. Fatih Demirkan

204 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Effects of bone marrow fibrosis and angiogenetic structure on autologous hematopoietic stem cell engraftment

    2017

    1 citation (OpenAlex) Source : OpenAlex

  2. Kemik iliği fibrozis ve anjiogenezisinin hematopoetik kök hücre engraftmanı üzerine etkisi

    Cukurova Medical Journal (Çukurova Üniversitesi Tıp Fakültesi Dergisi), 2017

    DOI 10.17826/cutf.296629 Texte intégral en libre accèsSource : OpenAlex

  3. Kronik Lenfositik Lösemi

    Turkiye Klinikleri Hematology - Special Topics, 2017

    Source : OpenAlex

  4. Kronik Myeloid Lösemi Tanılı Hastalarımızın Retrospektif Değerlendirilmesi

    DergiPark (Istanbul University), 2017

    Texte intégral en libre accèsSource : OpenAlex

  5. THE NEW PROGNOSTIC SIGNIFICANCE OFPLATELET-TO-LYMPHOCYTE RATIOS IN PATIENTSWITH MULTIPLE MYELOMA

    Çanakkale Onsekiz Mart University AVESIS, 2017

    Source : OpenAlex

  6. Kronik Myeloid Lösemi Tanılı Hastalarımızın Retrospektif Değerlendirilmesi

    Çanakkale Onsekiz Mart University AVESIS, 2017

    Source : OpenAlex

  7. A Multicenter Experience of Thrombotic Microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG) - TMA01 Study

    Blood, 2016

    DOI 10.1182/blood.v128.22.4933.4933 Texte intégral en libre accèsSource : OpenAlex

  8. A Multicenter Experience of Thrombotic Microangiopathies in Turkey The Turkish Hematology Research and Education Group ThREG TMA01 Study

    AYBU AVESIS, 2016

    Source : OpenAlex

  9. Otolog Hematopoetik Kök Hücre Nakli Planlanan Hastalarda Periferik Kök Hücre Mobilizasyonu Yaklaşımı Türkiye Hematolojik Araştırmalar Ve Eğitim Çalışma Grubu HKHN01 Çalışması Threg HSCT01

    AYBU AVESIS, 2016

    Source : OpenAlex

  10. 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

    Blood, 2016

    DOI 10.1182/blood.v128.22.2042.2042 10 citations (OpenAlex) Source : OpenAlex

  11. IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY

    Kölner Universitäts PublikationsServer (Universität zu Köln), 2016

    5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  12. Current Problems in the Management of Chronic Myeloid Leukemia in Turkey

    International Journal of Hematology and Oncology, 2016

    DOI 10.4999/uhod.11015 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  13. Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

    Blood, 2016

    DOI 10.1182/blood.v128.22.4403.4403 1 citation (OpenAlex) Source : OpenAlex

  14. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.

    Journal of Clinical Oncology, 2016

    DOI 10.1200/jco.2016.34.15_suppl.7525 8 citations (OpenAlex) Source : OpenAlex

  15. Is It Time for Early Cessation of Empirical Antibiotherapy in Patients Presenting with Febrile Neutropenia? Preliminary Results of a Risk-Adapted Approach in a Hematology Clinic

    Blood, 2016

    DOI 10.1182/blood.v128.22.2503.2503 Source : OpenAlex

  16. Is It Time for Early Cessation of Empirical Antibiotherapy in Patients Presenting with Febrile Neutropenia Preliminary Results of a Risk Adapted Approach in a Hematology Clinic

    AYBU AVESIS, 2016

    Source : OpenAlex

  17. The effect of stem cell viability and storage time

    DSpace - FIRAT (Fırat University), 2016

    Texte intégral en libre accèsSource : OpenAlex

  18. Post-Authorization Safety of Lenalidomide + Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2015

    DOI 10.1016/j.clml.2015.07.611 2 citations (OpenAlex) Source : OpenAlex

  19. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

    The Lancet Oncology, 2015

    DOI 10.1016/s1470-2045(15)00465-9 PMID 26655421 415 citations (OpenAlex) Source : OpenAlex

  20. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities

    Leukemia & lymphoma/Leukemia and lymphoma, 2015

    DOI 10.3109/10428194.2015.1014362 PMID 25669924 13 citations (OpenAlex) Source : OpenAlex

  21. Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

    Case Reports in Hematology, 2015

    DOI 10.1155/2015/425410 PMID 25705530 11 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  22. IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

    Clinical Lymphoma Myeloma & Leukemia, 2015

    DOI 10.1016/j.clml.2015.02.004 PMID 25790738 6 citations (OpenAlex) Source : OpenAlex

  23. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study

    Turkish Journal of Hematology, 2015

    DOI 10.4274/tjh.2013.0367 PMID 26316483 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  24. Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

    Blood, 2015

    DOI 10.1182/blood.v126.23.2936.2936 2 citations (OpenAlex) Source : OpenAlex

  25. 247 HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES

    Leukemia Research, 2015

    DOI 10.1016/s0145-2126(15)30248-4 1 citation (OpenAlex) Source : OpenAlex

  26. Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    Blood, 2015

    DOI 10.1182/blood.v126.23.2938.2938 1 citation (OpenAlex) Source : OpenAlex

  27. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial

    Kölner Universitäts PublikationsServer (Universität zu Köln), 2015

    1 citation (OpenAlex) Source : OpenAlex

  28. Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial

    Kölner Universitäts PublikationsServer (Universität zu Köln), 2015

    1 citation (OpenAlex) Source : OpenAlex

  29. Quality of Life in Multiple Myeloma: Validation of the Turkish Version of the Qlq-My20 Instrument

    Clinical Lymphoma Myeloma & Leukemia, 2015

    DOI 10.1016/j.clml.2015.07.442 2 citations (OpenAlex) Source : OpenAlex

  30. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.18_suppl.lba7005 18 citations (OpenAlex) Source : OpenAlex

  31. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.lba7005 5 citations (OpenAlex) Source : OpenAlex

  32. Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e18024 1 citation (OpenAlex) Source : OpenAlex

  33. Terapötik Aferezin Nefrolojik Hastalıklarda Kullanımı

    Turkiye Klinikleri Hematology - Special Topics, 2015

    Source : OpenAlex

  34. Ewing Sarkom Tedavisi Sonrası Gelişen Philadelphia Negatif Akut Lenfoblastik Lösemi Olgusu

    DergiPark (Istanbul University), 2015

    Texte intégral en libre accèsSource : OpenAlex

  35. Kronik Lenfositik Lösemi Tedavisinde Yeni Moleküller

    Turkiye Klinikleri Hematology - Special Topics, 2015

    Source : OpenAlex

  36. Iatrogenic Angiomatous Kaposi's Sarcoma of the Gingiva in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

    Oral Surgery Oral Medicine Oral Pathology and Oral Radiology, 2015

    DOI 10.1016/j.oooo.2014.07.409 Source : OpenAlex

  37. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers

    Chemotherapy, 2014

    DOI 10.1159/000375258 PMID 25871894 29 citations (OpenAlex) Source : OpenAlex

  38. Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion

    Clinical and Applied Thrombosis/Hemostasis, 2014

    DOI 10.1177/1076029614550817 PMID 25239946 9 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  39. Paroksismal Nokturnal Hemoglobinürili Olguların Değerlendirilmesi: İki Merkezin Deneyimi, S. Solmaz Medeni,

    Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 2014

    DOI 10.18614/deutfd.40684 Source : OpenAlex

  40. New paraneoplastic syndrome in chronic basophilic leukemia

    International Journal of Hematology, 2013

    DOI 10.1007/s12185-013-1281-4 PMID 23413035 5 citations (OpenAlex) Source : OpenAlex

  41. Successful hematopoietic engraftment with gray platelets after allogeneic hematopoietic stem cell transplantation from gray platelet syndrome donor

    Blood Coagulation & Fibrinolysis, 2013

    DOI 10.1097/mbc.0b013e32835aefc2 PMID 23358204 2 citations (OpenAlex) Source : OpenAlex

  42. The Management of Invasive Fungal Infections: What to Consider in Empirical Treatment?

    International Journal of Hematology and Oncology, 2013

    DOI 10.4999/uhod.13033 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  43. A New Method For Electronic Crossmatch: ABO /Rh Blood Group Confirmation and Antibody Screening Concomitantly With Serologic Crossmatch

    Blood, 2013

    DOI 10.1182/blood.v122.21.4833.4833 1 citation (OpenAlex) Source : OpenAlex

  44. Hemolitik Transfüzyon Reaksiyonları

    Turkiye Klinikleri Hematology - Special Topics, 2013

    Source : OpenAlex

  45. KMML Hastasında Santral Sinir Sisteminde Gelişen Myeloid Sarkom ve AML''ye Dönüşüm,

    DergiPark (Istanbul University), 2012

    1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  46. Kronik Lenfositik Lösemi Hastalarının Genel Klinik Değerlendirilmesi

    DergiPark (Istanbul University), 2012

    DOI 10.18614/deutfd.87368 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  47. Olgularımızın Retrospektif Tek Merkez Deneyimi: Folliküler Lenfomalı Değerlendirmesi,

    DSpace Repository, 2012

    DOI 10.18614/deutfd.81092 Source : OpenAlex

  48. İmmün Trombositopenili Hastaların Klinik Seyir ve Tedavi Cevabı Yönünden Değerlendirmesi; Tek Merkez Deneyimi

    DSpace Repository, 2012

    Source : OpenAlex

  49. The Effect Of Rituximab And Zoledronic Acid Combinations Againts Multiple Myeloma Cell Lines

    The Anatolian Journal of General Medical Research, 2012

    DOI 10.5222/terh.2012.25032 Texte intégral en libre accèsSource : OpenAlex

  50. Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient

    Blood Coagulation & Fibrinolysis, 2011

    DOI 10.1097/mbc.0b013e32834b8267 PMID 22123285 6 citations (OpenAlex) Source : OpenAlex